PLUS THERAPEUTICS, INC. Net Income Loss

• PLUS THERAPEUTICS, INC. showed a decrease of -72.5% in Net Income Loss from 2024 to 2025.
• This data is from PLUS THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), PLUS THERAPEUTICS, INC.'s Net Income Loss has grown by 3.6%.
• Historical annual values: Fiscal year 2025: -$22.39 million | Fiscal year 2024: -$12.98 million | Fiscal year 2023: -$13.32 million | Fiscal year 2022: -$20.28 million | Fiscal year 2021: -$13.40 million | Fiscal year 2020: -$8.24 million | Fiscal year 2019: -$10.89 million | Fiscal year 2018: -$12.63 million | Fiscal year 2017: -$22.69 million | Fiscal year 2016: -$22.05 million | Fiscal year 2015: -$18.74 million | Fiscal year 2014: -$37.37 million | Fiscal year 2013: -$26.18 million | Fiscal year 2012: -$32.28 million | Fiscal year 2011: -$32.45 million | Fiscal year 2010: -$27.49 million | Fiscal year 2009: -$23.22 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026